Skip to main content
. Author manuscript; available in PMC: 2006 Aug 1.
Published in final edited form as: Clin Cancer Res. 2005 Aug 1;11(15):5603–5615. doi: 10.1158/1078-0432.CCR-05-0670

Table 3.

Infection of DC (immature and matured with CD40L) with rF-TRICOM enhances avidity of CTL

Treatment of DC Avidity (M) of CTL Avidity vs DC (fold)* Avidity vs CD40L-matured DC (fold)**
DC 2.29 x 10−8 1.0 −2.3
DC infected with FP-WT 1.31 x 10−8 1.7 −1.3
DC infected with rF-TRICOM 3.5 x 10−10 65.4 28.0
DC matured with CD40L 9.81 x 10−9 2.3 1.0
DC matured with CD40L and infected with FP-WT 8.12 x 10−9 2.8 1.2
DC matured with CD40L and infected with rF-TRICOM 7.0 x 10−11 327.0 140.0

DC were generated with GM-CSF and IL-4 with or without maturation with CD40L and/or infected with rF-TRICOM or wild-type vector FP-WT, as described in Materials and Methods.

*

Numbers are the fold increase in avidity of activated T cells, as compared with those activated with DC generated with GM-CSF and IL-4.

**

Numbers are the fold increase or decrease in avidity of activated T cells, as compared with those activated with DC generated with GM-CSF and IL-4 and matured with CD40L.